Auxilium Pharmaceuticals, Inc.  

(Public, NASDAQ:AUXL)   Watch this stock  
Find more results for Nancy Elizabeth Adams�
19.35
-0.09 (-0.46%)
Jul 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 19.17 - 19.77
52 week 16.36 - 32.89
Open 19.58
Vol / Avg. 0.00/1.83M
Mkt cap 972.52M
P/E     -
Div/yield     -
EPS -1.33
Shares 50.26M
Beta 0.90
Inst. own 123%
Aug 4, 2014
Q2 2014 Auxilium Pharmaceuticals, Inc. Earnings Release (Estimated) Add to calendar
Jun 26, 2014
Auxilium Pharmaceuticals Inc to Merge with QLT Call - Webcast
Jun 24, 2014
Auxilium Pharmaceuticals Inc at JMP Securities Healthcare Conference
Jun 11, 2014
Auxilium Pharmaceuticals, Inc. at Goldman Sachs Healthcare Conference
Jun 3, 2014
Auxilium Pharmaceuticals, Inc. at Jefferies Global Healthcare Conference - Webcast
May 21, 2014
Auxilium Pharmaceuticals, Inc. Annual Shareholder Meeting
May 19, 2014
Auxilium Pharmaceuticals, Inc. at UBS Global Healthcare Conference
May 14, 2014
Auxilium Pharmaceuticals, Inc. at Bank of America Merrill Lynch Health Care Conference - Webcast
May 8, 2014
Auxilium Pharmaceuticals, Inc. at Deutsche Bank Healthcare Conference
May 5, 2014
Q1 2014 Auxilium Pharmaceuticals, Inc. Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin -63.24% -4.51%
Operating margin -52.04% -16.99%
EBITD margin - -3.47%
Return on average assets -18.73% -2.36%
Return on average equity -97.28% -8.00%
Employees 639 -
CDP Score - -

Address

640 LEE ROAD
CHESTERBROOK, PA 19087
United States - Map
+1-484-3215900 (Phone)
+1-484-3215999 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company focuses on developing and marketing products to predominantly specialist audiences. It market two products: Testim testosterone gel and XIAFLEX (collagenase clostridium histolyticum). XIAFLEX is an injectable clostridial collagenase enzyme approved by the United States Food and Drug Administration (FDA) for the treatment of Dupuytren's contracture (Dupuytren's) in adult patients with a palpable cord. Its Testim is a topical 1% testosterone once-a-day gel that treats hypogonadism by restoring normal testosterone blood levels for a 24-hour period following application and sustaining them in that range when used daily. Testim has been approved for marketing for the indication of male hypogonadism in the United States, Canada, Belgium, Denmark, Germany, Greece, Iceland, Ireland, Italy, Luxembourg, the Netherlands, Norway, Portugal, Spain, Sweden and the United Kingdom. In April 2013, it acquired Actient Holdings LLC.

Officers and directors

Rolf A. Classon Independent Chairman of the Board
Age: 69
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Adrian Adams President, Chief Executive Officer, Director
Age: 63
Bio & Compensation  - Reuters
James E. Fickenscher Chief Financial Officer
Age: 50
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Mark A. Glickman Executive Vice President - Marketing & Sales
Age: 48
Bio & Compensation  - Reuters
Benjamin J. Del Tito Jr., Ph.D. Executive Vice President - Regulatory Affairs and Project Management
Age: 58
Bio & Compensation  - Reuters
Alan J. Wills Executive Vice President - Corporate Development
Age: 50
Bio & Compensation  - Reuters
Jennifer L. Armstrong Senior Vice President - Human Resources
Age: 44
Bio & Compensation  - Reuters
Andrew I. Koven Chief Administrative Officer, General Counsel
Age: 56
Bio & Compensation  - Reuters
Elizabeth Varki Jobes Chief Compliance Officer
Age: 47
Bio & Compensation  - Reuters
James P. Tursi M.D. Chief Medical Officer
Age: 49
Bio & Compensation  - Reuters